Although inhibition of the multifaceted proteins PARP1 and PKM2 have been demonstrated to elicit therapeutic effects in preclinical models in reversing pulmonary vascular remodeling,13,24 their safety or even direct cardioprotective effects in the setting of PAH have never been investigated. The gene discussed is PARP1; the disease is pulmonary arterial hypertension.